When the whole patients’ population was analyzed, high mRNA expression of MSH6 (HR 0.82, 95% CI 0.71–0.96, P = 0.01), MLH1 (HR 0.83, 95% CI 0.7–0.98, P = 0.025), and PMS2 (HR 0.8, 95% CI 0.69–0.93, P = 0.0034) was associated with a significantly improved OS, whereas the mRNA expression of MSH2, MSH3, MLH3 and PMS1 genes was not related to OS of ovarian cancer treated with platinum-based chemotherapy (Fig. 1). This evidence concerns the gene MLH3 and ovarian carcinoma.